NINGBO KONFOONG BIOINFORMATION TECHNOLOGY CO.,LTD (“KFBIO”), founded in 2011, is a high-tech enterprise dedicated to the field of pathology, and a leading provider of integrated smart pathology solutions in China. The Company is primarily engaged in the research, development and production of pathology digitalisation products, pathology informatics products, pathology AI products and pathology pre-processing equipment, as well as pathology testing services.
KFBIO’s quality policy is: technological innovation, product excellence, customer satisfaction and social benefit. The Company is committed to quality management across the entire product lifecycle through the implementation of management system processes, standardised operations, and training and education. By embedding safety into its operational and quality management systems, we define and guide all our work to ensure the safety of consumers, customers and employees.
KFBIO is committed to ensuring product quality and consumer safety through the following measures:
- Complying with medical device regulations and other relevant laws and regulations in the countries where it operates, and, taking into account the Company’s actual circumstances, striving to meet or exceed country-specific safety standards.
- Implementing, maintaining and continuously improving a quality management system. Establishing a documented quality management system and preparing quality manuals, procedure documents and technical documents that comprehensively cover the full processes of design and development, raw material procurement, manufacturing, inspection and release, warehousing and transportation, installation and service, and after-sales support.
- Strengthening the management of supplier safety standards by applying a strict safety-standard admission system for suppliers and conducting regular supervision. Establishing supplier assessment, selection and dynamic management mechanisms, and conducting on-site audits and quality capability assessments of key suppliers.
- Building adverse event management and risk response mechanisms by establishing procedures for the detection, assessment, understanding and prevention of adverse events across the entire product lifecycle, and developing standardised workflows for adverse event reporting, investigation and handling.
- Driving continuous improvement of product safety through customer feedback. Establishing a customer complaint registration and handling system to systematically record all complaints involving product safety, conduct root-cause investigations, closed-loop handling and trend analysis, and feed the results of complaint handling into the quality management system as input for improvement.
- Enforcing strict post-market supervision and continuous performance tracking. Establishing a systematic post-market surveillance system, formulating post-market surveillance plans, and continuously collecting data on product performance and safety in actual use.
- Building product traceability and digital management capabilities. Using coding and identification technology to assign a unique device identifier to every device, enabling full traceability from production to end use.
- Fulfilling social responsibility and safeguarding public health and safety. Contributing to the advancement of public health and medical science through a variety of corporate social responsibility initiatives.
- Upholding compliant operations and integrity and ethics. Driving sustainable corporate development with a spirit of continuous improvement and responsibility, creating long-term value for patients, customers and society, and contributing to the development of global health.

